Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.38)
# 4,277
Out of 5,149 analysts
17
Total ratings
26.67%
Success rate
-22.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $75 | $7.52 | +897.34% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $1.69 | +846.75% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $0.10 | +9,353.78% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.89 | +105.66% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $30.42 | +228.73% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $0.42 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $3,750 | $2.29 | +163,655.46% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $0.92 | +1,526.55% | 1 | Jun 29, 2023 | |
| ATYR aTyr Pharma | Reinstates: Buy | $9 | $0.96 | +837.60% | 1 | Mar 6, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $2.64 | +695.45% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $90 | $51.88 | +73.48% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.52 | +12,201.59% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $1.16 | +2,896,451.72% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $75
Current: $7.52
Upside: +897.34%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $1.69
Upside: +846.75%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $0.10
Upside: +9,353.78%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.89
Upside: +105.66%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $30.42
Upside: +228.73%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.42
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $3,750
Current: $2.29
Upside: +163,655.46%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $0.92
Upside: +1,526.55%
aTyr Pharma
Mar 6, 2023
Reinstates: Buy
Price Target: $9
Current: $0.96
Upside: +837.60%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $2.64
Upside: +695.45%
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $51.88
Upside: +73.48%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.52
Upside: +12,201.59%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $1.16
Upside: +2,896,451.72%